Irregular menstrual cycles may be an early marker of ovarian cancer risk, according to a study presented at the annual meeting of the American Association for Cancer Research.
Women who carry a BRCA gene mutation and opt for a preventive oophorectomy had an 80% reduction in the risk of ovarian, fallopian tube, or peritoneal cancer.
A protein engineered to combine a molecule targeting a tumor-cell-surface antigen with another protein that stimulates immune functions was found to prolong survival in animal models for ovarian cancer and mesothelioma.
Researchers have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy.
A new type of strategy has been proposed to tackle an aggressive subtype of ovarian cancer by using a nanoscale drug-delivery system designed to target specific cancer cells.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|